# A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC

> **NCT06690671** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Lung Cancer, Non-Small Cell

## Interventions

- **DRUG:** Golidocitinib in combination with anti-PD-1

## Key facts

- **NCT ID:** NCT06690671
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-15
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06690671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06690671, "A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06690671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*